Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + dexamethasone vs pomalidomide + dexamethasone in t(11;14) relapsed/refractory multiple myeloma
jRCT2080224031Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of venetoclax in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Started Aug 2018; status: completed.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080224031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224031.